Palvella Therapeutics, Inc.
PVLA
$24.12
$0.2951.24%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 108.28% | -3.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 80.28% | -13.75% | |||
| Operating Income | -80.28% | 13.75% | |||
| Income Before Tax | -107.16% | 41.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -107.16% | 41.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -107.16% | 41.68% | |||
| EBIT | -80.28% | 13.75% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -142.96% | 74.89% | |||
| Normalized Basic EPS | -45.66% | 52.98% | |||
| EPS Diluted | -142.96% | 74.89% | |||
| Normalized Diluted EPS | -45.66% | 52.98% | |||
| Average Basic Shares Outstanding | 0.01% | 92.52% | |||
| Average Diluted Shares Outstanding | 0.01% | 92.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||